Kymera | Investor Presentation Deck | 60 slides

Slide schematic 4/4

chart 1/1 list 1/1 source-note 1/1 title 1/1

Components 4

bar-horizontal bullet source-note headline

Tools 1

list/bullet: Substantial downregulation of many disease relevant genes in both HS and AD patients. Downregulation exceeded 90% for many genes. Broad anti-inflammatory signature with downregulation of genes responsible fo

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

data-story-arc 80%

Uses specific clinical data to support a broader therapeutic claim.

Find anything

The slide uses individual patient data points (AD-1 to AD-7, HS-1 to HS-12) to show consistent downregulation across cohorts.